Corporate Presentation
January 2021
Disclaimer
Some of the statements contained in this presentation constitute forward-looking statements. Statements that are not historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward- looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue" or similar terminology. These statements are based on the Company's current strategy, plans, objectives, assumptions, estimates and projections. Investors should therefore not place undue reliance on those statements. The Company makes no representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Forward-looking statements speak only as of the date that they are made and the Company does not undertake to update any forward-looking statements in light of new information or future events. Forward- looking statements involve inherent risks and uncertainties. The Company cautions that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.
In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company is regularly reviewing the impact of the outbreak on its business. As of the date of this presentation, and based on publicly available information, the Company has not identified the occurrence of any material negative effect on its business due to the COVID-19 pandemic that remains unresolved. However, the Company anticipates that the COVID-19 pandemic could have further material negative impact on its business operations. The worldwide impact of COVID-19 may notably affect the Company's internal organization and efficiency, particularly in countries where it operates and where confinement measures are implemented by the authorities. In addition, COVID-19 may impact market conditions and the Company's ability to seek additional funding or enter into partnerships. Particularly, delays in the supply of drug substance or drug products, in the initiation or the timing of results of preclinical and/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could potentially have an impact on the Company's development programs and partnered programs. The Company will continue to actively monitor the situation.
2
Mission and Vision
To discover, develop and commercialize innovative therapies for patients suffering from
serious chronic diseases with underlying metabolic pathophysiology
- Mid-to-latestage first-in-class pipeline: Type 2 diabetes (globally partnered) and NASH
- Pipeline expansion in chronic and rare metabolic indications
- Internal AMPK* and D-TZD# Platforms o External Opportunities
Targeting Defects in Cellular Metabolism
acetyl CoA
METABOLICINFLAMMATION DISORDERS
(cellular energy
homeostasisTISSUE
imbalances) DEGENERATION & CELL DEATH
apoptosis, necrosis
Leveraging AMPK & D -TZD Platforms
Metabolic Component + Unmet Medical Need
- Hereditary Metabolic Disorders: e.g. adrenoleukodystrophy
- Endocrinopathies
-
Renal Diseases:
e.g. diabetic nephropathy, polycystic kidney disease, others - Other: rare, orphan indications
*AMP activated protein kinase; # Deuterium-stabilized thiazolidinediones.
3
Three Mid-to-Late Stage First-in-Class Drug Candidates with Novel Mechanisms and Differentiated Strategies
Key Partnership with T2D market leader in Japan
Novel Mechanisms with Platform Expansion
Proprietary Programs
Cash &
Equiv.4 EUR
41.5 million (USD 48.6
million) as of
9/30/20
Imeglimin
(T2D)
AMPK
PXL7702Platform
PXL0653D-TZD
Platform
Other
Chronic and
Rare Leveraging
Metabolic Platforms &
Indications External
Opportunities
Anticipated first product launch in Japan in 2021 through Imeglimin partnership with Sumitomo Dainippon
Pharma
Several significant milestones over the next two years including Phase 2 results in biopsy-proven patients in NASH
Highly experienced management team; extensive metabolic R&D expertise &
track record in US, EU and Japan
Global company with presence in 3 countries (France, US and Japan); listed on Euronext Paris
1. including: China, South Korea, Taiwan, Indonesia, Vietnam, Thailand, Malaysia, the Philippines, Singapore, Myanmar, Cambodia, and Laos. 2. PLX770 direct AMP-kinase activator (AMPK) from platform. 3. PXL065 deuterium-stabilizedR-pioglitazone (mitochondrial pyruvate inhibitor) from D-TZD (deuterated thiazolidinediones) platform. 4 Does not include EUR 6 million PFG loan obtained in October 2020.
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Poxel SA published this content on 15 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 January 2021 19:09:04 UTC